80 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
, no deficiency assessment with respect to a proposed adjustment of the Company’s or the Subsidiaries’ federal, state, local or foreign taxes is pending
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
determination that, based on an assessment of the preliminary data from the Phase 3 clinical development program, diazoxide choline may demonstrate substantial
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
that, based on an assessment of the preliminary data from the Phase 3 clinical development program, diazoxide choline may demonstrate substantial improvement
8-K
EX-99.1
SLNO
Soleno Therapeutics Inc
29 Apr 24
First Ever Breakthrough Designation for a Drug Being Developed for PWS
4:08pm
. The designation reflects the Agency’s determination that, based on an assessment of the preliminary data from the Phase 3 clinical development program
8-K
EX-10.1
yk4ycqk iu
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.1
mcmqipohgvb
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
6sf 1wkcbhh6o9ovi
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
xvh6bj9m
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-99.1
cpr1k8v4rpeg3gvsqer
26 Sep 23
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
7:30am
8-K
6219x4kx6t5t3qpf
16 Aug 23
Departure of Directors or Certain Officers
9:00am
8-K
EX-10.1
n06hfucvs7w899ndosx
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm